• CCS1477 is the first drug to be used in patients that specifically targets p300/CBP, offering a new route to treat specific drug-resistant cancers
• Trial in late stage prostate cancer well underway across multiple clin­i­cal centres, under the leadership of Johann de Bono of The Royal Marsden Hospital, The Institute of Cancer Research, London
• Dosing in patients with haematological malig­nan­cies has now begun, starting at the Christie Hospital, Manchester

Cambridge, United Kingdom (Press Release) – CellCentric has ex­panded the clin­i­cal devel­op­ment pro­gramme of its novel anti-cancer drug CCS1477, a highly potent and specific small molecule inhibitor of p300/CBP. Dosing has commenced in a new study involving patients with multiple myeloma and will in­clude those with acute myeloid leukaemia and cer­tain lym­phomas. Trials are already underway for patients with late stage drug resistant prostate cancer.

Dr Nigel Brooks, CellCentric’s Director of Translational Science, commented: “Inhibiting p300/CBP is of growing interest to researchers. …